Aminex Therapeutics, Inc. is focused on bringing its breakthrough discoveries to the clinic to improve the lives of cancer patients.  Our small molecule, first-in-class anti-metabolite approach (PBT) should be useful against many hyper-proliferative disease states, yet due to the strong animal efficacy data in hand; it is the strategy of the company to pursue its use for Head and Neck/Squamous Cell Carcinoma (HNSCC) as its first cancer indication. Animex Therapeutics’ recent experiments have demonstrated that PBT has a unique mechanism of action that, when viewed in conjunction with durable cures observed following treatment in animals; give it a clear competitive market advantage.

Competitive advantages include:

·        First-in-class anticancer agents based on 3 issued US Patents

·        Animal proof-of-concept in mice and house cats

·        Demonstration of unique mechanism of action that promises to re-frame the oncology product market

·         Preclinical work supported by National Cancer Institute RAID grant

·         Extraordinary opportunity to quickly advance our advanced pre-clinical approach to the benefit of cancer patients worldwide

Aminex: It's what's next in Cancer Therapeutics

Last update 12/18/2009